Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

about

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Item

http://www.wikidata.org/entity/Q55361920

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@en

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@nl

type

Item

label

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@en

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@nl

prefLabel

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@en

Baseline splenic volume as a s ...... advanced pancreatic carcinoma.

@nl

P1476

Baseline splenic volume as a s ...... advanced pancreatic carcinoma

@en

P2093

Angélique Vienot

http://www.w3.org/2001/XMLSchema#string

Anne Aarnink

http://www.w3.org/2001/XMLSchema#string

Caroline Truntzer

http://www.w3.org/2001/XMLSchema#string

Christophe Borg

http://www.w3.org/2001/XMLSchema#string

Corentin Richard

http://www.w3.org/2001/XMLSchema#string

Julie Vincent

http://www.w3.org/2001/XMLSchema#string

Leila Bengrine

http://www.w3.org/2001/XMLSchema#string

P2860

The spleen in local and systemic regulation of immunity

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.

Boosting for high-dimensional time-to-event data with competing risks.

Neutrophil count is associated with myeloid derived suppressor cell level and presents prognostic value of for hepatocellular carcinoma patients.

P304

25617-25629

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25424

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francois Ghiringhelli

P577

2018-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29876012

http://www.w3.org/2001/XMLSchema#string

P932

5986639

http://www.w3.org/2001/XMLSchema#string